On Friday, Pfizer and Seagen submitted a merger proposal worth $43 billion to the Federal Trade Commission and the Department of Justice. According to a filing on Monday, Pfizer intends to acquire Seagen for $229 per share in cash.
The premerger filing submitted on Friday initiates a 15-day waiting period in accordance with the FTC’s regulations for a cash tender offer. The transaction can proceed if the waiting period elapses without any objections from the FTC.
The US agency may require more information, referred to as a “second request,” which can extend the review process.
The deal between the two drugmakers is being closely monitored by industry watchers, as it is the largest M&A deal in the pharmaceutical industry since the announcements of the megamergers between Bristol Myers Squibb and Celgene, and between AbbVie and Allergan, both in 2019 and valued at $74 billion and $63 billion, respectively.
Related: Pfizer In $5B Talks To Buy Global Blood Therapeutics
The FTC issued second requests for both deals and required certain asset sales to address antitrust concerns.
Pfizer ended their partnership with Merck KGa on Bavencio, possibly due to concerns over antitrust scrutiny regarding a bladder cancer business overlap. Bavencio is commonly used as a front-line maintenance therapy for bladder cancer patients who responded to initial chemotherapy.
Seagen and Astellas’ drug, Padcev, received FDA approval as an initial treatment for bladder cancer in patients who cannot undergo cisplatin-based chemotherapy. Ongoing clinical trials are being conducted to explore the possibility of further use of Padcev in treating bladder cancer.
Due to the size of the Pfizer and Seagen deal, it is possible that they may need to resubmit their premerger report to allow for additional time for the FTC review. This has been seen in smaller transactions, such as Sanofi’s purchase of Provention Bio for $2.9 billion.
Featured News
BHP Unveils £31bn Mining Megamerger Proposal with Anglo American
Apr 25, 2024 by
nhoch@pymnts.com
ByteDance Prefers Shutdown Over Sale of TikTok Amid US Ban Threats
Apr 25, 2024 by
CPI
FCC Votes to Restore Net Neutrality Rules
Apr 25, 2024 by
nhoch@pymnts.com
Apple Rejects Spotify’s Updated App Over In-App Pricing Disclosure
Apr 25, 2024 by
CPI
FCC Set to Reinstate Net Neutrality Rules Today
Apr 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI